We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.06%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$278M
AUM Growth
+$69.7M
Cap. Flow
+$59.7M
Cap. Flow %
21.48%
Top 10 Hldgs %
34.47%
Holding
97
New
38
Increased
13
Reduced
9
Closed
33

Top Buys

1
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$7.55M
2
CYH icon
Community Health Systems
CYH
+$7.52M
3
CELG
Celgene Corp
CELG
+$7.17M
4
MRK icon
Merck
MRK
+$5.93M
5
SAGE
Sage Therapeutics
SAGE
+$5.16M

Top Sells

1
GILD icon
Gilead Sciences
GILD
+$6.13M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$5.28M
3
ASRT
Assertio
ASRT
+$4.83M
4
NVRO
NEVRO CORP.
NVRO
+$4.45M
5
INSY
Insys Therapeutics, Inc.
INSY
+$4.22M

Sector Composition

1 Healthcare 71.61%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVNC
26
DELISTED
Revance Therapeutics, Inc.
RVNC
$4.15M 1.49%
+200,000
New +$3.46M
GWPH
27
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.1M 1.47%
+45,000
New +$3.65M
ABBV icon
28
AbbVie
ABBV
$450B
$4.1M 1.47%
+70,000
New +$4.23M
ADVM
29
CALL
DELISTED
Adverum Biotechnologies
ADVM
$4.05M 1.46%
+10,000
New +$4.23M
ACAD icon
30
Acadia Pharmaceuticals
ACAD
$4.38B
$3.91M 1.41%
+120,000
New +$4.12M
EXAS
31
DELISTED
Exact Sciences
EXAS
$3.85M 1.39%
+175,000
New +$4.44M
FOLD
32
DELISTED
Amicus Therapeutics
FOLD
$3.81M 1.37%
350,000
+50,000
+17% +$441K
ACHN
33
DELISTED
Achillion Pharmaceuticals
ACHN
$3.7M 1.33%
+375,000
New +$4.68M
PTCT icon
34
PTC Therapeutics
PTCT
$6.52B
$3.65M 1.31%
60,000
-25,000
-29% -$1.53M
TXMD icon
35
TherapeuticsMD
TXMD
$23.8M
$3.63M 1.31%
12,000
-736
-6% -$180K
BLUE
36
DELISTED
bluebird bio
BLUE
$3.62M 1.3%
2,316
– –
AVDL
37
DELISTED
Avadel Pharmaceuticals
AVDL
$3.6M 1.29%
200,000
-125,000
-38% -$1.96M
INGN icon
38
Inogen
INGN
$178M
$3.52M 1.27%
+110,000
New +$3.55M
VTAE
39
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$3.51M 1.26%
+300,000
New +$4.05M
DBVT
40
DBV Technologies
DBVT
$870M
$3.5M 1.26%
15,000
+7,000
+88% +$1.66M
NSTG
41
DELISTED
NanoString Technologies, Inc.
NSTG
$3.41M 1.23%
335,000
+245,000
+272% +$3.01M
ENTL
42
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$3.29M 1.18%
+150,000
New +$3.24M
RDUS
43
DELISTED
Radius Health, Inc.
RDUS
$3.09M 1.11%
+75,000
New +$3.37M
WINT
44
DELISTED
Windtree Therapeutics Inc
WINT
$2.98M 1.07%
+178,571
New +$3.52M
PTX
45
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$2.67M 0.96%
+25,000
New +$2.38M
RXDX
46
DELISTED
Ignyta, Inc.
RXDX
$2.49M 0.89%
+250,000
New +$1.87M
IOVA icon
47
Iovance Biotherapeutics
IOVA
$2.23B
$2.42M 0.87%
+200,000
New +$2.25M
TTPH
48
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.38M 0.86%
+3,250
New +$2.44M
AGTC
49
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.33M 0.84%
+116,750
New +$2.61M
FPRX
50
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.29M 0.82%
+100,000
New +$2.52M
1
2
3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2015 Portfolio in Review

As of Q1 2015, Ghost Tree Capital held 97 positions worth $278M, up 33% from $208M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ghost Tree Capital deployed $59.7M of net new capital in Q1 2015, opening 38 new positions and adding to 13 existing holdings. Its largest new stake was ZS PHARMA INC COMS TK (DE): 165,000 shares worth $6.94M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 69% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Advaxis Inc, an estimated $3.06M trimmed.

  • Ghost Tree Capital's largest Q1 2015 buy was ZS PHARMA INC COMS TK (DE): 165,000 shares worth $6.94M.
  • Ghost Tree Capital added most to Allergan plc in Q1 2015, an estimated $4.99M increase.
  • Ghost Tree Capital's biggest Q1 2015 reduction was Advaxis Inc, cutting an estimated $3.06M.
  • Ghost Tree Capital fully exited Gilead Sciences in Q1 2015, selling an estimated $6.13M.
  • Ghost Tree Capital's ten largest holdings make up 34% of its $278M portfolio in Q1 2015.
  • Ghost Tree Capital opened 38 new positions and closed 33 in Q1 2015.
  • Ghost Tree Capital's portfolio value rose 33% quarter-over-quarter to $278M.

Based on Ghost Tree Capital's 13F filing for Q1 2015, filed 15 May 2015.